Esperite N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
16 mrt 2015 - 07:23
Statutaire naam
Esperite N.V.
Titel
Esperite (ESP) and Premaitha Health sign a collaboration agreement for NIPT provision in Europe
Bericht
Manchester, UK and Zutphen, the Netherlands - 16 March 2015 - Premaitha Health plc ("Premaitha", AIM: NIPT) and Esperite NV ("Esperite", AMS: ESP, Zutphen, the Netherlands) today announce the signing of an agreement under which Genoma SA ("Genoma", Geneva, Switzerland), the fully owned subsidiary of Esperite will have the right to use Premaitha's CE-IVD IONA® test for its non-invasive prenatal testing (NIPT) service called TRANQUILITY®. Access to Premaitha's test will allow Genoma to apply the CE-IVD marking to its NIPT for trisomies 21, 18 and 13.
The IONA® test is the first CE-marked in vitro diagnostic (IVD) product for NIPT. It uses next-generation sequencing (NGS) technology to estimate the risk of a fetus having Down's syndrome (Trisomy 21), Edwards' syndrome (Trisomy 18) and Patau's syndrome (Trisomy 13) by analysing cell-free fetal DNA from a sample of maternal blood.
Gerelateerde downloads
Datum laatste update: 29 juli 2024